Document Detail

Milrinone for long-term therapy of severe heart failure: clinical experience with special reference to maximal exercise tolerance.
MedLine Citation:
PMID:  3510777     Owner:  NLM     Status:  MEDLINE    
Thirty-seven patients with severe chronic heart failure were entered into an open-ended trial with milrinone at an initial daily dose ranging form 20 to 30 mg. Mean duration of treatment was 48 weeks and ranged from 1 to 134 weeks. Twenty-five patients (67%) reported a substantial improvement in well-being with less dyspnea or fatigue, but this was not associated with a significant increase in maximal oxygen uptake: 10.2 +/- 2.9 vs 10.7 +/- 2.4 ml/kg/min (NS). At intervals ranging from 6 to 54 weeks, they experienced a recurrence of symptoms that was partially reversed by increasing the dose of milrinone to a maximum of 50 mg/day. In 15 patients whose symptoms could not be controlled by milrinone alone, captopril was added. The combination of captopril and milrinone was well tolerated and produced a symptomatic improvement in 10 of the 15 patients (67%). Maximal oxygen uptake, however, was not significantly increased by addition of captopril to milrinone: 10.6 +/- 2.7 vs 11.6 +/- 3.3 ml/kg/min. Twenty-four patients died: 12 of sudden death and 12 of gradual worsening of heart failure. During prolonged administration of milrinone, no patient experienced overt clinical adverse reactions directly attributable to the drug. Left ventricular end-diastolic dimension increased from 3.6 +/- 0.7 to 4.1 +/- 0.9 cm/m2 (p less than .05) after a mean duration of 50 weeks of milrinone therapy. Accordingly, long-term therapy with milrinone appears to improve functional status without eliciting overt clinical adverse reactions. However, the possibility that milrinone might have contributed to the high mortality noted during this therapeutic trial cannot be excluded.(ABSTRACT TRUNCATED AT 250 WORDS)
T H LeJemtel; D Gumbardo; B Chadwick; H I Rutman; E H Sonnenblick
Related Documents :
3075397 - Indications and effects of captopril therapy in childhood.
18617127 - The effect of metoprolol on perioperative outcome in coronary patients undergoing nonva...
10091817 - Tolerability and efficacy of carvedilol in patients with new york heart association cla...
18803997 - Adherence with multiple-combination antihypertensive pharmacotherapies in a us managed ...
25309867 - Correction of angle class ii division 1 malocclusion with a mandibular protraction appl...
8800307 - Cavity foot ulcers in diabetic patients: a comparative study of cadexomer iodine ointme...
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Circulation     Volume:  73     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1986 Mar 
Date Detail:
Created Date:  1986-03-21     Completed Date:  1986-03-21     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  III213-8     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Captopril / therapeutic use
Cardiotonic Agents / pharmacology,  therapeutic use*
Chronic Disease
Clinical Trials as Topic
Drug Therapy, Combination
Heart Failure / drug therapy*,  mortality
Middle Aged
Oxygen Consumption / drug effects
Physical Exertion / drug effects*
Pyridones / pharmacology,  therapeutic use*
Time Factors
Reg. No./Substance:
0/Cardiotonic Agents; 0/Pyridones; 62571-86-2/Captopril; 78415-72-2/Milrinone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Assessment of long-term therapy with milrinone and the effects of milrinone withdrawal.
Next Document:  Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (M...